Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Possible thiabendazole-induced theophylline toxicity

A M Sugar, P J Kearns, A A Haulk

    The American Review of Respiratory Disease
    |September 1, 1980
    PubMed
    Summary

    Thiabendazole, used for strongyloidiasis in immunocompromised patients, can cause theophylline toxicity. This drug interaction may occur because thiabendazole interferes with theophylline clearance.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    AN OVARIAN PREGNANCY.

    Canadian Medical Association journal·2010
    Same author

    A CASE OF SARCOMA BOTRYIODES CORPORIS UTERI.

    Canadian Medical Association journal·2010
    Same author

    PLACENTA INCRETA.

    Canadian Medical Association journal·2010
    Same author

    A CASE OF PRIMARY CARCINOMA OF THE FALLOPIAN TUBE.

    Canadian Medical Association journal·2010
    Same author

    A RARE DEVELOPMENTAL ANOMALY OF THE UTERUS COMPLICATED BY PREGNANCY AND RUPTURE.

    Canadian Medical Association journal·2010
    Same author

    A COMPARATIVE STUDY OF HUMAN OVA.

    Canadian Medical Association journal·2010

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Clinical Toxicology

    Background:

    • Strongyloidiasis is a parasitic infection often requiring prolonged treatment.
    • Immunosuppressed patients are particularly vulnerable to severe strongyloidiasis.
    • Thiabendazole is a common antihelminthic used for treating strongyloidiasis.

    Observation:

    • A case of theophylline toxicity was observed in a patient receiving concurrent thiabendazole.
    • This represents the first reported instance of this specific drug interaction.
    • The patient's clinical presentation indicated significant theophylline toxicity.

    Findings:

    • Concurrent administration of thiabendazole and theophylline can lead to theophylline toxicity.
    • Preliminary evidence suggests thiabendazole interferes with theophylline clearance.
    • This drug interaction highlights a potential risk in managing co-infected or co-morbid patients.

    Implications:

    • Clinicians should be aware of the potential for thiabendazole-theophylline drug interaction.
    • Monitoring theophylline levels is crucial when co-administering these drugs.
    • Further research is needed to elucidate the precise mechanism of this interaction and guide clinical practice.

    Related Experiment Videos